Limits...
Immunohistochemical expression of Src protein in peripheral and central giant cell granulomas of the jaws.

Khiavi MM, Aghbali AA, Halimi M, Kouhsoltani M, Hamishehkar H - J Oral Maxillofac Pathol (2013)

Bottom Line: There were no significant differences in the Src expression and the SID score between PGCG and CGCG.Furthermore, Spearman's rank correlation coefficient showed that there was a significant correlation between Src expression and SID score within both PGCG and CGCG (P < 0.001; r = 0.87 and 0.75, respectively).In addition, differences in immunoreactivity of this osteoclastic protein do not reflect different clinical behaviors of PGCG and CGCG.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral Pathology, Faculty of Dentistry, Tehran University of Medical Sciences, International Campus, Tehran, Iran.

ABSTRACT

Aim and objective: The aim of this study was to investigate the expression of Src protein (an osteoclastic factor) in peripheral and central giant cell granulomas (PGCG and CGCGs) of the jaws and the relationship between the expression of this protein and the clinical behavior of these two lesions.

Materials and methods: Thirty cases of PGCG and 30 cases of CGCG were immunohistochemically stained with Src. A staining-intensity-distribution (SID) score (proportion of stained cells × staining intensity) was used to evaluate immunoreactivity of the protein. Data were analyzed using statistical package for social sciences (SPSS) 17.0.

Results: There were no significant differences in the Src expression and the SID score between PGCG and CGCG. Furthermore, Spearman's rank correlation coefficient showed that there was a significant correlation between Src expression and SID score within both PGCG and CGCG (P < 0.001; r = 0.87 and 0.75, respectively).

Conclusion: The findings of this study suggest that the multinucleated giant cells share some similarities with osteoclasts and Src protein can be used as a new therapeutic target to inhibit osteoclastic activity. In addition, differences in immunoreactivity of this osteoclastic protein do not reflect different clinical behaviors of PGCG and CGCG.

No MeSH data available.


Related in: MedlinePlus

The means of Src expression and staining-intensity-distribution (SID) score with error bars in two groups with confidence interval of 95%
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3927335&req=5

Figure 2: The means of Src expression and staining-intensity-distribution (SID) score with error bars in two groups with confidence interval of 95%

Mentions: In this study, immunohistochemical evaluation confirmed the presence of Src in both the PGCG [Figure 1b] and the CGCG [Figure 1c]. Mann-Whitney U-test did not show statistically significant difference neither in the Src expression (P = 0.057) nor the SID score (P = 0.09) between PGCG and CGCG [Figure 2]. However, Src expression was considerably higher in CGCG [Table 1]. Spearman's rank correlation coefficient showed a significant correlation between Src expression and SID score in both the PGCG (r = 0.87, P < 0.001) and the CGCG (r = 0.75, P < 0.001) [Figure 3].


Immunohistochemical expression of Src protein in peripheral and central giant cell granulomas of the jaws.

Khiavi MM, Aghbali AA, Halimi M, Kouhsoltani M, Hamishehkar H - J Oral Maxillofac Pathol (2013)

The means of Src expression and staining-intensity-distribution (SID) score with error bars in two groups with confidence interval of 95%
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3927335&req=5

Figure 2: The means of Src expression and staining-intensity-distribution (SID) score with error bars in two groups with confidence interval of 95%
Mentions: In this study, immunohistochemical evaluation confirmed the presence of Src in both the PGCG [Figure 1b] and the CGCG [Figure 1c]. Mann-Whitney U-test did not show statistically significant difference neither in the Src expression (P = 0.057) nor the SID score (P = 0.09) between PGCG and CGCG [Figure 2]. However, Src expression was considerably higher in CGCG [Table 1]. Spearman's rank correlation coefficient showed a significant correlation between Src expression and SID score in both the PGCG (r = 0.87, P < 0.001) and the CGCG (r = 0.75, P < 0.001) [Figure 3].

Bottom Line: There were no significant differences in the Src expression and the SID score between PGCG and CGCG.Furthermore, Spearman's rank correlation coefficient showed that there was a significant correlation between Src expression and SID score within both PGCG and CGCG (P < 0.001; r = 0.87 and 0.75, respectively).In addition, differences in immunoreactivity of this osteoclastic protein do not reflect different clinical behaviors of PGCG and CGCG.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral Pathology, Faculty of Dentistry, Tehran University of Medical Sciences, International Campus, Tehran, Iran.

ABSTRACT

Aim and objective: The aim of this study was to investigate the expression of Src protein (an osteoclastic factor) in peripheral and central giant cell granulomas (PGCG and CGCGs) of the jaws and the relationship between the expression of this protein and the clinical behavior of these two lesions.

Materials and methods: Thirty cases of PGCG and 30 cases of CGCG were immunohistochemically stained with Src. A staining-intensity-distribution (SID) score (proportion of stained cells × staining intensity) was used to evaluate immunoreactivity of the protein. Data were analyzed using statistical package for social sciences (SPSS) 17.0.

Results: There were no significant differences in the Src expression and the SID score between PGCG and CGCG. Furthermore, Spearman's rank correlation coefficient showed that there was a significant correlation between Src expression and SID score within both PGCG and CGCG (P < 0.001; r = 0.87 and 0.75, respectively).

Conclusion: The findings of this study suggest that the multinucleated giant cells share some similarities with osteoclasts and Src protein can be used as a new therapeutic target to inhibit osteoclastic activity. In addition, differences in immunoreactivity of this osteoclastic protein do not reflect different clinical behaviors of PGCG and CGCG.

No MeSH data available.


Related in: MedlinePlus